---
title: "Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285394236.md"
description: "Giant Biogene Holding Co. Ltd. has scheduled its annual general meeting for May 28, 2026, in Xi’an. Shareholders will review the 2025 financial statements and vote on the re-election of three executive directors and the appointment of KPMG as the new auditor. The meeting will also address mandates for share repurchase and issuance, potentially impacting capital management and shareholder returns. The current analyst rating for the stock (HK:2367) is a Buy with a price target of HK$38.70."
datetime: "2026-05-06T14:08:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285394236.md)
  - [en](https://longbridge.com/en/news/285394236.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285394236.md)
---

# Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Giant Biogene Holding Co. Ltd. ( (HK:2367) ).

Giant Biogene Holding Co., Ltd. has called its annual general meeting for 28 May 2026 in Xi’an, where shareholders will review the audited financial statements for the year ended 31 December 2025 and consider the re-election of three executive directors, including Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo. Investors will also vote on appointing KPMG as the new independent auditor following the retirement of Ernst & Young, and on granting the board fresh mandates to repurchase up to 10% of the company’s issued shares and to issue additional shares, moves that could give management greater flexibility over capital structure and future financing.

These resolutions, if approved, would refresh key corporate governance authorizations and may signal a shift in the company’s audit oversight as well as its approach to capital management. The share repurchase and issuance mandates, bounded by Hong Kong listing rules, could influence liquidity and shareholder returns, while the continuity of the executive team suggests strategic stability as the company heads into its next financial year.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$38.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

**More about Giant Biogene Holding Co. Ltd.**

Giant Biogene Holding Co., Ltd. is a Cayman Islands–incorporated company listed in Hong Kong, operating in the biotechnology and life sciences sector. The company focuses on developing and commercializing biological and related products, and is subject to the regulatory and governance framework of the Hong Kong capital markets.

**Average Trading Volume:** 5,200,695

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$31.97B

For an in-depth examination of 2367 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02367.HK](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

- [Morgan Stanley Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367)](https://longbridge.com/en/news/270232349.md)
- [Citic Securities Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367)](https://longbridge.com/en/news/283910584.md)
- [<![CDATA[Politics, Capital Markets, Misinformation and the Impact on Biotech: Q&A with Jeremy Levin]]>](https://longbridge.com/en/news/286751503.md)
- [Heineken Holding N.V. reports transactions under its current share buyback programme | HKHHY Stock News](https://longbridge.com/en/news/286751233.md)
- [PTA-DD: Warimpex Finanz- und Beteiligungs AG: Managers' transactions announcement according to article 19 MAR](https://longbridge.com/en/news/286901864.md)